Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.
Study of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections.
1 other identifier
observational
180
1 country
27
Brief Summary
The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2004
Typical duration for all trials
27 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2004
CompletedFirst Submitted
Initial submission to the registry
September 12, 2005
CompletedFirst Posted
Study publicly available on registry
September 19, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2007
CompletedSeptember 25, 2009
September 1, 2009
3.1 years
September 12, 2005
September 24, 2009
Conditions
Keywords
Interventions
Eligibility Criteria
Patients treated at internal medicine units
You may qualify if:
- Hospitalized patients over 16 years of age with complicated urinary infection produced by bacteria that are suspected to be susceptible to treatment with Piperacillin-tazobactam.
You may not qualify if:
- Patients known, or thought to be hypersensitivity to beta-lactams
- Patients with an uncomplicated urinary tract infection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (27)
Unknown Facility
Antequera (Málaga), Spain
Unknown Facility
Ávila, Spain
Unknown Facility
Barcelona, Spain
Unknown Facility
Berga (Barcelona), Spain
Unknown Facility
Cadiz, Spain
Unknown Facility
Castellon, Spain
Unknown Facility
Cáceres, Spain
Unknown Facility
Ciudad Real, Spain
Unknown Facility
Cuenca, Spain
Unknown Facility
Ferrol, Spain
Unknown Facility
Granada, Spain
Unknown Facility
Jaén, Spain
Unknown Facility
Las Palmas, Spain
Unknown Facility
Lleida, Spain
Unknown Facility
Lorca (Murcia), Spain
Unknown Facility
Lugo, Spain
Unknown Facility
Madrid, Spain
Unknown Facility
Osuna (Sevilla), Spain
Unknown Facility
Palma Mallorca, Spain
Unknown Facility
Pamplona, Spain
Unknown Facility
Pontevedra, Spain
Unknown Facility
Terrassa, Spain
Unknown Facility
Torrelavega, Spain
Unknown Facility
Valencia, Spain
Unknown Facility
Valladolid, Spain
Unknown Facility
Vitoria-Gasteiz, Spain
Unknown Facility
Zaragoza, Spain
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Medical Monitor
Wyeth is now a wholly owned subsidiary of Pfizer
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
September 12, 2005
First Posted
September 19, 2005
Study Start
June 1, 2004
Primary Completion
July 1, 2007
Study Completion
July 1, 2007
Last Updated
September 25, 2009
Record last verified: 2009-09